Who is sponsoring NCT04153747?

NCT04153747 is sponsored by Hospital Universitario La Paz.

What drugs are being tested in NCT04153747?

Interventions in NCT04153747: High-power and short-duration radiofrequency ablatio (70 W / 9-10 s), Low-power (25-40 W) radiofrequency ablation guided by lesion size index (LSI) and ablation index (AI) values, Esophageal endoscopy, Daily 30-seconds ECG.

What condition does NCT04153747 study?

NCT04153747 studies Atrial Fibrillation, Catheter Ablation.

Is NCT04153747 still recruiting?

NCT04153747 is currently completed. Last updated 10 January 2024.

Last reviewed 2024-01-10 · How we verify

NCT04153747: POWER-FAST

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

High Radiofrequency Power for Faster and Safer Pulmonary Vein Ablation Trial (POWER FAST III)

Completed NA Last updated 10 January 2024

What this trial tests

NA trial testing High-power and short-duration radiofrequency ablatio (70 W / 9-10 s) in Atrial Fibrillation in 304 participants. Completed in 30 December 2023.

Timeline

25 April 2019

Primary endpoint
30 April 2023

30 December 2023

Quick facts

Lead sponsor	Hospital Universitario La Paz
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	304
Start date	25 April 2019
Primary completion	30 April 2023
Estimated completion	30 December 2023
Sites	1 location across Spain

Drugs / interventions tested

High-power and short-duration radiofrequency ablatio (70 W / 9-10 s)
Low-power (25-40 W) radiofrequency ablation guided by lesion size index (LSI) and ablation index (AI) values
Esophageal endoscopy
Daily 30-seconds ECG

Conditions studied

Atrial Fibrillation — all drugs for Atrial Fibrillation →
Catheter Ablation — all drugs for Catheter Ablation →

Sponsor

Hospital Universitario La Paz

Who can join

18 and older, any sex, with Atrial Fibrillation or Catheter Ablation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multicenter 1:1 randomized study. Two atrial fibrillation ablation strategies are compared: 1) conventional ablation using point-by-point radiofrequency applications with power 40 W guided by LSI \> 6 or AI \> 500 on the anterior aspect of pulmonary veins and power 25 W guided by LSI \>5 or AI \>350 on the posterior wall near the esophagus; 2) point-by-point RF applications with power set at 70 W and duration 9-10 s. The main objective of the trial is the incidence of esophageal lesions evaluated with systematic endoscopy and clinical efficacy evaluated with daily ECG transtelephonic transmissions during 1-year follow-up. Secondary objectives include total RF time and parameters of acute PV isolation efficacy (first-pass isolation, acute reconnections and dormant conduction).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

High-Power Short-Duration Radiofrequency Application for Faster and Safer Pulmonary Vein Isolation: The POWER-FAST III Trial.
Castrejón-Castrejón S, Martínez Cossiani M, Basterra Sola N, Romero Roldán JD, et al · · 2025 · cited 8× · PMID 39708035 · DOI 10.1016/j.jacep.2024.10.009

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

NCT07429214 — A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF · NA · recruiting
NCT07271238 — Feasibility Study on the VERAFEYE Imaging and Navigation System for Guided Catheter Ablation Procedures · NA · recruiting
NCT07388108 — Atrial Dyssynchrony to Predict Arrhythmias in the Postoperative Setting of Cardiovascular Surgery. · recruiting
NCT07428967 — AV Node Ablation and CONDUCTion System Pacing for Atrial Fibrillation With Preserved Left Ventricular Function · NA · recruiting
NCT06650995 — AlEX-DHF: Ablation and Exercise in Diastolic Heart Failure · NA · recruiting

Other Hospital Universitario La Paz trials

Trials by the same sponsor.

NCT07479927 — Telematic Cognitive Training and Mindfulness in Pediatric Patients After CAR-T Cell Therapy, Single Hematopoietic Alloge · NA · recruiting
NCT07260643 — SiLaC Laser Technique for Pilonidal Sinus - La Paz Cohort Study. · not yet recruiting
NCT07203664 — Use of Tacrolimus and MTOR Inhibitors With Anticipatory Therapy vs. Tacrolimus and Mycophenolic Acid With Universal Prop · Phase 4 · not yet recruiting
NCT07023601 — International Prospective Multicentre Study That Evaluate the Sentinel Lymph Node Detection Rate in Patients With First · NA · enrolling by invitation
NCT03086850 — Long-term Effect of the Physical Activity Promotion on the Clinical Characteristics and Vascular Risk in Patients With M · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04153747 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospital Universitario La Paz
Last refreshed: 10 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04153747.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing